Sionna Therapeutics (NASDAQ:SION) Shares Down 4.7% – Here’s Why

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) were down 4.7% during trading on Monday . The company traded as low as $33.39 and last traded at $33.6980. Approximately 63,269 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 345,553 shares. The stock had previously closed at $35.37.

Wall Street Analyst Weigh In

A number of equities analysts have commented on SION shares. Citizens Jmp reiterated a “market outperform” rating and issued a $63.00 price objective on shares of Sionna Therapeutics in a report on Tuesday, May 26th. Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. BTIG Research reiterated a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Guggenheim boosted their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.22.

Sionna Therapeutics Price Performance

The firm’s 50-day moving average price is $40.47 and its 200 day moving average price is $39.89. The firm has a market cap of $1.49 billion, a P/E ratio of -17.03 and a beta of 1.30.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Analysts forecast that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Activity

In related news, Director Orbimed Advisors Llc sold 184,639 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the sale, the director owned 2,671,822 shares in the company, valued at $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the transaction, the director directly owned 2,671,822 shares in the company, valued at $123,491,612.84. This represents a 6.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,717,962 shares of company stock worth $77,571,889. 5.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Several large investors have recently made changes to their positions in SION. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics in the third quarter valued at approximately $30,000. BNP Paribas Financial Markets acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at approximately $31,000. GF Fund Management CO. LTD. acquired a new stake in shares of Sionna Therapeutics in the fourth quarter valued at approximately $36,000. Balyasny Asset Management L.P. acquired a new stake in shares of Sionna Therapeutics in the fourth quarter valued at approximately $58,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sionna Therapeutics in the fourth quarter valued at approximately $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.